Drug Profile
Dihydroergotamine mesilate intranasal - Satsuma Pharmaceuticals
Alternative Names: Dihydroergotamine mesilate - Satsuma Pharmaceuticals; Dihydroergotamine mesylate - Satsuma Pharmaceuticals; STS-101; TO-2070Latest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator Shin Nippon Biomedical Laboratories
- Developer Satsuma Pharmaceuticals
- Class Antimigraines; Ergotamines; Mesylates; Small molecules
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Migraine
Most Recent Events
- 18 May 2023 Satsuma Pharmaceuticals anticipates a PDUFA action date of January 2024 for the NDA submission to US FDA for Migraine
- 18 May 2023 US FDA accepts NDA for dihydroergotamine mesilate intranasal in Migraine for review
- 22 Apr 2023 Interim adverse events data from the phase III ASCEND trial in Migraine presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)